- Home
- BRX vs JAZZ Comparison
BRX vs JAZZ Comparison
Compare BRX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRX
- JAZZ
- Stock Information
- Founded
- BRX 2011
- JAZZ 2003
- Country
- BRX United States
- JAZZ Ireland
- Employees
- BRX N/A
- JAZZ N/A
- Industry
- BRX Real Estate Investment Trusts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- BRX Real Estate
- JAZZ Health Care
- Exchange
- BRX Nasdaq
- JAZZ Nasdaq
- Market Cap
- BRX 7.9B
- JAZZ 7.1B
- IPO Year
- BRX 2013
- JAZZ 2007
- Fundamental
- Price
- BRX $27.87
- JAZZ $123.11
- Analyst Decision
- BRX Strong Buy
- JAZZ Strong Buy
- Analyst Count
- BRX 12
- JAZZ 12
- Target Price
- BRX $30.17
- JAZZ $182.75
- AVG Volume (30 Days)
- BRX 2.2M
- JAZZ 842.6K
- Earning Date
- BRX 07-28-2025
- JAZZ 08-05-2025
- Dividend Yield
- BRX 4.26%
- JAZZ N/A
- EPS Growth
- BRX 12.30
- JAZZ N/A
- EPS
- BRX 1.09
- JAZZ N/A
- Revenue
- BRX $1,326,128,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- BRX $5.75
- JAZZ $6.10
- Revenue Next Year
- BRX $4.42
- JAZZ $5.07
- P/E Ratio
- BRX $25.57
- JAZZ N/A
- Revenue Growth
- BRX 5.27
- JAZZ 4.52
- 52 Week Low
- BRX $22.29
- JAZZ $95.49
- 52 Week High
- BRX $30.67
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- BRX 66.96
- JAZZ 66.95
- Support Level
- BRX $26.85
- JAZZ $105.00
- Resistance Level
- BRX $27.25
- JAZZ $117.21
- Average True Range (ATR)
- BRX 0.55
- JAZZ 3.36
- MACD
- BRX 0.13
- JAZZ 0.77
- Stochastic Oscillator
- BRX 93.09
- JAZZ 95.12
About BRX Brixmor Property Group Inc.
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.